Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (New York)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity.
Alexander R., Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J.
CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, New York City, September 18, 2015, Poster B008, Session B.